Europe Chronic Idiopathic Constipation Drug Market Forecast 2017-2025

Friday, July 21, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 20, 2017 /PRNewswire/ -- KEY FINDINGS The Europe chronic idiopathic

constipation drug market is estimated to grow at a CAGR of 6.08% during the forecast years of 2017-2025.The market value is estimated to increase from $434.7 million in 2016 and reach $738.73 million
by 2025. Download the full report: https://www.reportbuyer.com/product/5012010/MARKET INSIGHTS The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. The market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones. The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is the leading drug in the market. COMPETITIVE INSIGHTS The top players in the market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A. Download the full report: https://www.reportbuyer.com/product/5012010/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com

Tel: +44 208 816 85 48 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/europe-chronic-idiopathic-constipation-drug-market-forecast-2017-2025-300491804.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook